Why did Divi's Laboratories (DIVISLAB) stock move recently?

On 8/4/2026, Divi's Laboratories moved +4.0% — Divi's Labs shares rose on a strong Q1 FY27 beat, with net profit surging 66% YoY to ₹902 crore and revenue up 28% to ₹3,080 crore, beating estimates, alongside management reaffirming double-digit revenue growth guidance for FY27. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Divi's Laboratories (DIVISLAB) overvalued or fairly valued?

MarketChacha shows Divi's Laboratories's valuation in context — a forward P/E of about 55.2, a price-to-book of about 13.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Divi's Laboratories's revenue?

Divi's Laboratories reported revenue of ₹10,388 Cr for FY2026, with net profit of ₹2,607 Cr, per official filings.

What is the share price of Divi's Laboratories (DIVISLAB)?

Divi's Laboratories last traded at ₹8,578.50 (+3.4% on the day), as of 8/11/2026 — a delayed quote shown for education, not investment advice.

Divi's Laboratories

DIVISLAB · NSE · Pharma · India

Snapshot

TickerDIVISLAB

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees11,565

HeadquartersHyderabad, India

Websitewww.divislabs.com

Filings tracked0

About Divi's Laboratories

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Who owns it

Promoters52.0%
Institutions30.0%
Public & other18.0%

222 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend23.5% → 25.1%

Margin has expanded by about 1.6 points — the business is getting more profitable.

Growth qualityrev 10% · PAT 13%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (BSE (official results filing)). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹2,933 Cr · EPS 30.67

Est. earnings growth +18.1%

Next fiscal year

Rev ₹14,989 Cr · EPS 150.33

Est. earnings growth +22.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Annual

Quarterly · last 5

Revenue (FY2026)

₹10,388 Cr

Net margin

25.1%

Revenue CAGR (3y)

+10.2%

Profit CAGR (3y)

+12.7%

EPS (FY2026)

98.19

Net profit (FY2026)

₹2,607 Cr

Ask MarketChacha about DIVISLAB

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 4, 2026
Divi's Labs shares rose on a strong Q1 FY27 beat, with net profit surging 66% YoY to ₹902 crore and revenue up 28% to ₹3,080 crore, beating estimates, alongside management reaffirming double-digit revenue growth guidance for FY27.
source 1 ↗source 2 ↗source 3 ↗· confidence: high
Jul 29, 2026
Divi's Laboratories shares rose with the broader Indian market and likely the pharma sector, which advanced on positive sentiment with no company-specific catalyst identified.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹10,388 Cr	₹2,607 Cr	98.19	25.1%
FY2025	₹9,360 Cr	₹2,191 Cr	—	23.4%
FY2024	₹7,845 Cr	₹1,600 Cr	—	20.4%
FY2023	₹7,768 Cr	₹1,823 Cr	—	23.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	₹2,974 Cr	₹891 Cr	33.55	30.0%
2026Q1	₹2,793 Cr	₹756 Cr	28.44	27.1%
2025Q4	₹2,578 Cr	₹598 Cr	22.56	23.2%
2025Q3	₹2,715 Cr	₹689 Cr	—	25.4%
2025Q2	₹2,410 Cr	₹545 Cr	—	22.6%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.